Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia | Biomarker Research | Full Text

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia | Biomarker Research | Full Text

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia

The original article [1] contains an error in the legend of Fig. 1 whereby it is incorrectly stated that MEC stands for ‘mitoprostate cancer using magnetic resonance imagingxantrone, etoposide, cyclophosphamid...

Authors:Juanjuan Zhao, Yongping Song and Delong Liu

Citation:Biomarker Research 2019 7:21

Content type:Correction

Published on: 17 October 2019

The original article was published in Biomarker Research 2019 7:19

• ViewFull Text
 
• ViewPDF

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia

FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) remains as one of the most frequently mutated genes in acute myeloid leukemia (AML), especially in those with normal cytogenetics. The FLT3-IT...

Authors:Juanjuan Zhao, Yongping Song and Delong Liu

Citation:Biomarker Research 2019 7:19

Content type:Review

Published on: 11 September 2019

The Correction to this article has been published in Biomarker Research 2019 7:21

• ViewFull Text
 
• ViewPDF
•